At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,131 enrolled / 1,131 target
Drug / intervention
Bimekizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
In Brief
A Phase 3 clinical trial evaluating Bimekizumab for Psoriatic Arthritis. Completed, enrolled 1,131 participants across 138 sites in 14 countries.
Signals
Enrolling slower than its timeline implies
Detailed Summary
This is a study to assess the long-term safety, long-term efficacy and tolerability of bimekizumab administered subcutaneously (sc) in adult subjects with psoriatic arthritis (PsA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
CountriesAustralia, Belgium, Canada, Czechia, France, Germany, Hungary, Italy, Japan, Poland, Russia, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedJul 2019
Enrollment StartAug 2019
Primary CompletionMay 2026
TodayJul 2026
First PostedJul 5, 2019
Enrollment StartAug 13, 2019
Primary CompletionMay 26, 2026
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 7.0 years ago
Arms & Interventions
Bimekzumab dosage regimenexperimental
Subjects participating in the study will receive assigned bimekizumab dosage regimen during the Treatment Period.
Drug: Bimekizumab
Interventions
Bimekizumabdrug
Subjects will receive bimekizumab at pre-specified time-points.